Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Phesgo Market Growth Potential: How Will Market Size Shift Through 2030?
The historical period’s growth was driven by an escalating diagnosis of HER2-positive breast cancer, progress in monoclonal antibody development, the expansion of oncology infusion centers, better survival outcomes from targeted therapy, and a surge in biologic drug approvals.
The anticipated growth during the forecast period is primarily driven by the wider implementation of home-based oncology treatment models, increased investments in combination biologic therapies, the growing adoption of subcutaneous drug delivery methods, advancements in formulation stability technologies, and a rising demand for efficient cancer treatment protocols. Major trends expected within the forecast period include the increasing uptake of fixed-dose combination therapies, a growing preference for subcutaneous oncology treatments, the expansion of therapies for HER2-positive breast cancer, an intensifying focus on patient convenience and compliance, and continuous enhancements in biologic formulation technologies.
Get A Free Sample Report With In-Depth Market Insights:
Phesgo Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The rising number of breast cancer cases is anticipated to fuel the expansion of the phesgo market. Breast cancer originates in the cells of the breast, often within milk ducts or lobules, and can metastasize. This surge in incidence is linked to an aging population, genetic predispositions, changes in lifestyle, environmental exposures, and hormonal factors. Phesgo offers a beneficial, fixed-dose combination of pertuzumab and trastuzumab, two targeted therapies that work together to inhibit the HER2 protein responsible for tumor growth and progression, thereby aiding breast cancer patients by reducing administration time and enhancing the overall treatment experience. For example, the American Cancer Society, a US-based professional body, reported an increase in new breast cancer diagnoses in the United States from 300,590 in 2023 to 313,510 in 2024. Consequently, the growing incidence of breast cancer is a key factor propelling the phesgo market. The increasing need for personalized medicine is expected to drive the growth of the phesgo market in the future. Personalized medicine involves customizing medical treatment to suit each patient’s unique attributes, such as their genetic makeup, lifestyle, and environment, to deliver more effective and targeted therapies. The escalating demand for personalized medicine stems from advancements in genomics, which enable tailored treatments that enhance patient outcomes and minimize side effects. Phesgo contributes to personalized medicine by integrating pertuzumab and trastuzumab, targeted therapies designed to block the HER2 protein in HER2-positive breast cancer patients, into a single subcutaneous injection. This streamlines treatment delivery and aligns with individual patient requirements for precise care. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, noted that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. These 2023 approvals also included seven cancer drugs and three for other conditions. Therefore, the expanding demand for personalized medicine is a significant driver for the phesgo market.
Phesgo Market Breakdown By Product Type And Application
The phesgo market covered in this report is segmented –
1) By Indication: Early Breast Cancer, Metastatic Breast Cancer
2) By Formulation: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors
4) By End User: Hospitals, Oncology Clinics, Home Healthcare
Phesgo Market Innovation Trends Shaping Future Development
Key companies operating in the phesgo market are prioritizing the introduction of innovative therapies, such as monoclonal antibody combination therapy, to improve treatment effectiveness and patient outcomes in oncology. Monoclonal antibody combination therapy is defined as the simultaneous application of two or more monoclonal antibodies to target distinct facets of a disease, often resulting in better treatment success and the circumvention of potential resistance mechanisms. For instance, in November 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, introduced Phesgo combination for Subcutaneous Injection MA, IN. Phesgo is an injectable combination medication that delivers pertuzumab and trastuzumab, both monoclonal antibodies, together with hyaluronidase alfa, for the treatment of HER2-positive breast cancer and advanced HER2-positive colorectal cancer, providing a convenient subcutaneous administration option instead of intravenous infusion.
Phesgo Market Company Landscape And Competitive Strategy
Major companies operating in the phesgo market are F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd.
View The Full Phesgo Market Report:
Phesgo Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the phesgo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phesgo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
